TORONTO, Dec. 12, 2017 /CNW/ - A new study published by the Canadian Health Policy Institute (CHPI) concludes that there is no spending crisis regardingpatented drugs in Canada. Adjusting for real economic factors like population, CPI and GDP, the total direct cost burden from patented drugs is stable and moderate. Prices are also stable and moderate relative to CPI
The analysis used data from the Patented Medicine Prices Review Board (PMPRB), the Canadian Institute for Health Information (CIHI), and Statistics Canada.
The study found that:
The paper, "Facts about the cost of patented drugs in Canada", was published at CHPI's online journal, Canadian Health Policy, and can be accessed at www.canadianhealthpolicy.com.
SOURCE Canadian Health Policy Institute
Subscribe to our Free Newsletters!
Blood groups are of four important groups determined by the presence or absence of specific ...
Spermatocele is a condition in which there is a blockage in the epididymal duct, resulting in semen ...
Be a blood donor and save lives for your donated blood is separated into blood products or just ...View All